We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias.
Patients with acceptable performance status (0-2), adequate organ function, and no active …

Background Ruxolitinib is a potent and specific JAK1/JAK2 inhibitor recently approved for
the treatment of myelofibrosis. Patients and Methods We conducted a single-center phase I/II …

Leukemic or blast phase transformation occurs in~ 2.3–14.4% of patients with polycythemia
vera at 10 years and 5.5–18.7% at 15 years; the corresponding rates for essential …

BACKGROUND Polycythemia vera (PV) is a myeloproliferative neoplasm associated with
somatic gain‐of‐function mutations of Janus kinase‐2 (JAK2). Therapeutic options are …

Ruxolitinib (INCB-018424) is a potent, orally available, selective inhibitor of both JAK1 and
JAK2 of the JAK-STAT signaling pathway, being developed by Incyte Corp and Novartis AG …

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus
kinases, was approved by the US Food and Drug Administration for the treatment of patients …

Abstract On November 16, 2011, the Food and Drug Administration approved ruxolitinib (a
JAK1 and JAK2 inhibitor) for use in the treatment of high and intermediate risk myelofibrosis …

The BCR-ABL-negative myeloproliferative neoplasm, primary or post-ET/PV myelofibrosis
(MF), is chronic hematological malignancy with a median survival of o5 years. 1 Allogeneic …

Ruxolitinib, formerly known as INCB018424 or INC424, is a potent and selective oral
inhibitor of Janus kinase (JAK) 1 and JAK2. Ruxolitinib has been approved for the treatment …

Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being
developed for clinical use. Its major cellular and systemic effects are proliferation inhibition …